Laura P.
- Country
- Italy
- Department
- Unità Oncologia Medica
Research Overview
- Evaluation of Trastuzumab Deruxtecan and Fluoropyrimidine Versus Standard Chemotherapy in HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease
- A Phase III Randomized Double-Blind Study of Pembrolizumab, Trastuzumab, and Chemotherapy in HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Evaluation of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab in Advanced Melanoma: A Randomized, Double-Blind, Phase 2/3 Study
Data & Insights
Has run more than one trial at 51 of 207 partner sites.
Specializations
Gastrointestinal Oncology
Specializes in advanced treatment approaches for colorectal cancer and gastroesophageal cancers, with particular focus on stage-specific interventions and precision medicine strategies.
- Stage IV Colorectal Cancer Management
- HER2-Positive Gastric Cancer Treatment
- Adjuvant Therapy Optimization
Investigates innovative therapeutic combinations for gastrointestinal malignancies using targeted biological agents.
Precision Oncology
Focuses on liquid biopsy applications and circulating tumor DNA analysis for treatment monitoring and personalized therapy selection.
- Molecular Biomarker Assessment
- RAS/BRAF Mutation Analysis
- Treatment Response Monitoring
Implements advanced diagnostic techniques to guide therapeutic decision-making in cancer treatment.
Immunotherapy Research
Conducts research in advanced melanoma treatment and novel immunotherapy combinations, particularly focusing on checkpoint inhibitor therapy.
- Pembrolizumab-Based Combinations
- Novel Immunotherapy Agents
- Treatment Response Assessment
Evaluates innovative immunotherapeutic approaches for various cancer types.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.